Harmony Biosciences
✦ Quant Fair Value how this is computed
- Implied fair-value range of 8.24-102.53, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -41.2% below the average-multiple fair value of 55.38.
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Harmony Biosciences (HRMY) | 1.91B | 10.79 | 1.78 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 9.2% below Morningstar's fair value estimate.
Fair value
Harmony Biosciences Holdings Inc receives a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 5% discount to our quantitative fair value estimate of $35.60 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
The company's profitability strengthens our fair value estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 10.6%, which lies in the top 20% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are undervalued.
Alternatively, the company's balance sheet is potentially concerning. Low leverage can limit a company's ability to invest in growth, potentially reducing shareholder value compared with a balanced use of debt and equity financing. The firm's current ratio of 3.4, for example, sits in the top 30% compared with global peers. This suggests that management of working capital may be "lazy", tying up valuable capital that could be considered excessive and leading to a lower return on invested capital. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Harmony Biosciences discussion 0 comments